Immunomedics Inc. (NASDAQ:IMMU)’s share price traded up 4.9% on Monday . The stock traded as high as $2.84 and last traded at $2.78, with a volume of 650,868 shares trading hands. The stock had previously closed at $2.65.

Several equities analysts have weighed in on the company. Wells Fargo & Co. cut Immunomedics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 21st. Zacks Investment Research raised Immunomedics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 6th. Finally, Jefferies Group raised Immunomedics from a “hold” rating to a “buy” rating and raised their target price for the company from $1.50 to $5.00 in a research report on Friday, May 6th. They noted that the move was a valuation call.

The firm’s market capitalization is $265.45 million. The stock’s 50 day moving average is $2.49 and its 200 day moving average is $2.76.

Immunomedics (NASDAQ:IMMU) last posted its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. On average, equities research analysts predict that Immunomedics Inc. will post ($0.57) earnings per share for the current year.

In related news, CEO Cynthia L. Goldenberg sold 63,959 shares of the company’s stock in a transaction on Monday, June 6th. The stock was sold at an average price of $4.09, for a total value of $261,592.31. Following the sale, the chief executive officer now directly owns 703,029 shares of the company’s stock, valued at $2,875,388.61. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Cynthia L. Goldenberg sold 41,441 shares of the company’s stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $3.62, for a total value of $150,016.42. Following the completion of the sale, the chief executive officer now directly owns 703,029 shares in the company, valued at $2,544,964.98. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Immunomedics stock. Marshall Wace LLP purchased a new stake in Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned 0.90% of Immunomedics as of its most recent SEC filing.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.